Ambu's CEO remains confident of job security despite run of bad news

One downgrade has been followed by another at medtech company Ambu, and CEO Juan Jose Gonzalez has yet to show shareholders any share value growth – but if his seat his getting warmer, he isn’t feeling it.

Ambu's CEO Juan Jose Gonzalez isn't showing signs of pressure despite having had to announce a string of downgrades to the company's guidance, as share price continues to plummet | Photo: Carsten Snejbjerg/Ritzau Scanpix

Despite a string of downgrades and adjustments in Ambu’s past three consecutive quarters, as well as circulating rumors that CEO Juan Jose Gonzalez’s seat is getting hotter, the man himself rejects the notion that his position is in jeopardy.

In May 2019, Gonzalez stepped into Ambu’s headquarters in the Danish town of Ballerup for the first time. Since then, he has been the company’s figurehead as six downgrades and adjustments have come and gone – the latest of which occurred today, in connection with Tuesday’s quarterly report. Share price growth, which despite some fluctuations has been on a steady decline of 12 percent since he was appointed, has been conspicuously absent.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

In a world of options, Genmab's CEO chose partnerships

In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.

Analyst predicts slow start for Leo Pharma's Adtralza in UK

The take-up of Leo Pharma’s atopic eczema drug Adtralza in the UK will be slow-going, according to analyst bureau Global Data, after the British institute NICE released draft guidance where it was not recommend it as a standard treatment in England and Wales.

Further reading

Related articles

Latest news

See all jobs